Talk:Eutylone

From PsychonautWiki
(Redirected from Eutylone)
Jump to navigation Jump to search
Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: Eutylone
Eutylone
Eutylone.svg
Chemical Nomenclature
Common names Eutylone, bk-EBDB
Substitutive name N-Ethylbutylone
Systematic name β-Keto-1,3-benzodioxolyl-N-ethylbutanamine
Class Membership
Psychoactive class Stimulant / Entactogen
Chemical class Cathinone
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Common 50 - 80 mg
Duration
Total 4 - 8 hours



Insufflated
Dosage
Threshold 5 mg
Light 15 - 45 mg
Common 45 - 80 mg
Strong 80 - 125 mg
Heavy 125 mg +
Duration
Total 3 - 6 hours
Onset 15 - 45 minutes
Come up 15 - 30 minutes
Peak 30 - 60 minutes
Offset 30 - 90 minutes
After effects 2 - 4 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


Eutylone (also known as β-keto-1,3-benzodioxolyl-N-ethylbutanamine, bk-EBDB, N-Ethylbutylone, or euty) is a stimulant which has been reported as a novel designer drug and has appeared in 2019 being sold as a designer drug. As a designer drug, it is commonly sold among research chemical vendors as a substitute for, or counterfeit of MDMA and methylone, due to methylone's declining availability on the research chemical market. Despite behavioral and pharmacological similarities between eutylone and MDMA, the reported subjective effects of the two are not completely identical. Eutylone's effects are often described as being reminiscent of MDMA, but with a shorter duration and weaker effects.[1]

Subjective effects include stimulation, thought acceleration, motivation enhancement, increased libido, appetite suppression dehydration, dry mouth , and euphoria, Euthylone is reported to be less potent than its relatives butylone, methylone and ethylone as well as possessing more classic stimulant as opposed to entactogenic effects.

Euthylone has a short history of human use and very little data exists about its pharmacological properties, metabolism, and toxicity. It is highly advised to use harm reduction practices if using this substance.

Chemistry

Eutylone is a synthetic substance of the cathinone family. Cathinones are structurally similar to amphetamines in that they contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional ethyl substitution at Rα. Cathinones such as eutylone are alpha-methylated phenethylamines (i.e. amphetamines) but differ from them with the addition of a ketone functional group (a carbonyl group at Rβ).

Pharmacology

Eutylone acts as a mixed reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine.[2][3] Eutylone modulates theseneurotransmitters in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of the neurotransmitters back into the cell after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused, causing physically stimulating and euphoric effects.

In comparison to methylone, it has much lower affinity for the norepinephrine transporter, while its affinity for the serotonin and dopamine transporters is similar.[4][5] Despite this lower affinity, eutylone is a stronger reuptake inhibitor than MDMA, although it is less potent and has a more balanced catecholaminergic profile. As a mixed releaser and reuptake inhibitor, it also has relatively robust releasing capabilities.[6]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
Child.svg

Cognitive effects
User.svg

After effects
Aftereffects (3).svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found on the subreddit /r/researchchemicals

Toxicity and harm potential

The toxicity and long-term health effects of recreational Eutylone use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because Eutylone has very little history of human usage. Anecdotal evidence from people who have tried Eutylone within the community suggests that there do not seem to be strong adverse effects attributed to using this substance at low to moderate doses and sparingly.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other stimulants, the chronic use of Eutylone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of eutylone develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Eutylone presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of Eutylone all stimulants will have a reduced effect.

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[7] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[8][9] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[10] Psychosis very rarely arises from therapeutic use.[11][12]

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with Eutylone should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • Stimulants - Eutylone may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • Tramadol - Tramadol is known to lower the seizure threshold[13] and combinations with stimulants may further increase this risk.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.


See also

External links

References

  1. "Cathinone | Ask Dr. Shulgin Online". 
  2. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/10528135
  3. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
  4. "Pharmacological characterization of designer cathinones in vitro" | http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02145.x/pdf
  5. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
  6. "Pharmacological characterization of designer cathinones in vitro" | http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02145.x/pdf
  7. Treatment for amphetamine psychosis | [1]
  8. Treatment for amphetamine psychosis | [2]
  9. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  10. Treatment for amphetamine psychosis | [3]
  11. Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
  12. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
  13. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  14. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.